Recurrences were more likely in PCMZL, and mutations in TNFAIP3 and FAS were not identified in primary cutaneous CD4‐positive small/medium lymphoproliferative disorder [77]. This evidence concerns the gene TNFAIP3 and primary cutaneous marginal zone B-cell lymphoma.